FDA Brief

Warning letters Drugs

FDA warning letter to

Santhigram Kerala Ayurvedic Co. of U.S., Inc.

High riskIssued May 19, 2022Posted May 24, 2022Center for Drug Evaluation and Research | CDER

FDA told Santhigram Kerala Ayurvedic Co. of U.S. that its ayurvedic products are unapproved new drugs sold with disease claims online.

What happened

FDA reviewed the company's website at http://www.santhigram.us in March 2022 and its Facebook and Instagram pages, which direct consumers to the website to buy products. FDA found product pages and social posts claiming the ayurvedic products treat diseases, including "COVID CARE KIT" claims for Smokers Kit/Respiratory Care Kit and Immunocare Kit.

What FDA found

  1. FDA says website and social media claims make the ayurvedic products drugs intended to diagnose, cure, mitigate, treat, or prevent disease or to affect body structure or function.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA says the products are new drugs because they are not generally recognized as safe and effective for their labeled uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. FDA says the company sells these new drugs without the required FDA approval.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  4. FDA says Smokers Kit/Respiratory Care Kit and Immunocare Kit are labeled COVID CARE KIT and claimed to mitigate, prevent, treat, diagnose, or cure COVID-19.

    FD&C Act sections 201(g)(1), 201(p), 505(a), and 301(d)
  5. FDA says drug claims appear on the website and social media for a wide range of products, not only the products named in the letter.

  6. FDA says the products are introduced or delivered for introduction into interstate commerce without prior approval.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA asks the company to take immediate action to stop selling any unapproved and unauthorized products for COVID-19. FDA also asks for a written response within 15 working days describing steps taken, documentation, and plans to prevent recurrence, or the reason and timeline if corrective actions cannot be completed.

Who should pay attention

  • online sellers of ayurvedic or herbal products with disease claims
  • brands and websites that make COVID-19 treatment claims
  • retailers or platforms hosting unapproved drug claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk